Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28260625 | 0.83 | CYP3A4 (0.59) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL14022813 | 0.82 | CYP3A4 (0.53) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL28326178 | 0.82 | CYP3A4 (0.53) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL28005285 | 0.81 | CYP3A4 (0.51) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL8334750 | 0.81 | CYP3A4 (0.56) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL28246238 | 0.79 | CYP3A4 (0.74) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL28796104 | 0.78 | CA2 (0.37) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL20132835 | 0.78 | NAAA (0.53) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL27563795 | 0.78 | CYP3A4 (0.49) | CYP3A4TSHRTDP1ATMCA2 | |
| SCHEMBL12923909 | 0.78 | CYP3A4 (0.49) | CYP3A4TSHRTDP1ATMCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0414655-A1 | Improved process for the production of carbonate esters | MONSANTO COMPANY (US) | 1991-02-27 | — | — | EP | claimed |
| US-20150307454-A1 | Sulfonamide Compound | KALLYOPE, INC. | 2015-10-29 | — | — | US | disclosed |
| WO-2011092284-A1 | NOVEL AMINO ACID DERIVATIVES AND THEIR USE AS GPR43 RECEPTOR MODULATORS | EUROSCREEN S.A. (BE) | 2011-08-04 | — | — | WO | disclosed |
| EP-2120569-A2 | SPIROCHROMANON DERIVATIVES | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2111406-A1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | Merck & Co., Inc. (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008088688-A1 | SUBSTITUTED SPIROCHROMANONE DERIVATIVES AS ACC INHIBITORS | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008088692-A2 | SPIROCHROMANON DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-0381135-A2 | Novel hydroxy-peroxides and their uses | ATOCHEM NORTH AMERICA, INC. (US) | 1990-08-08 | — | — | EP | disclosed |
| EP-0273990-A1 | Novel organic peroxides and their use in the preparation of epoxide groups containing (co)polymers | AKZO N.V. (NL) | 1988-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307454-A1 | Sulfonamide Compound | TRPM8, TRPM5, TRPM7 | CYP3A4 1795/4885TSHR 799/4885TDP1 4632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.